查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細胞和基因治療製造服務市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按類型、適應症、應用、最終用戶和地理位置
市場調查報告書
商品編碼
1362428

細胞和基因治療製造服務市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按類型、適應症、應用、最終用戶和地理位置

Cell and Gene Therapy Manufacturing Services Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Indication, Application, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 216 Pages | 訂單完成後即時交付

價格

細胞和基因治療製造服務市場規模預計將從2022年的75.8197億美元成長到2030年的26​​7.249億美元；預計2022-2030年年複合成長率為 17.1%。

本報告強調了市場的普遍趨勢以及推動和阻礙細胞和基因治療製造服務市場成長的因素。市場的成長歸因於細胞和基因療法批准數量的增加以及外包細胞和基因療法製造的日益普及。然而，細胞和基因療法製造的高成本阻礙了市場的成長。

公司的策略舉措

在細胞和基因治療製造服務市場中營運的公司致力於策略發展，例如合作、擴張、協議、夥伴關係和新產品發布，這有助於他們提高銷售、擴大地理覆蓋範圍並增強迎合市場需求的能力。比現有的客戶群更大。以下提到了細胞和基因治療製造服務市場的一些值得注意的發展。

2023年 5月，Lonza 推出了 TheraPEAK T-VIVO 細胞培養基，採用新型化學成分確定的配方，目的是最佳化和簡化 CAR T 細胞的製造。與其他無血清培養基不同，TheraPEAK T-VIVO 細胞培養基無需添加人類血清或其成分即可表現出高性能。

2022年10月，輝瑞公司完成了對Biohaven Pharmaceutical Holding Company Ltd.的收購，Biohaven Pharmaceutical Holding Company Ltd.是NURTEC ODT(rimegepant)的製造商，NURTEC ODT(rimegepant)是一種創新的偏頭痛療法，核准用於成人發作性偏頭痛的急性治療和預防。

2022年 3月，Cellevolve Bio 與西雅圖兒童治療公司合作，開發和商業化用於兒童癌症的新型多重 CAR。根據此次合作，合作夥伴將致力於 BrainChild 研究計畫，該計畫由五種多重 CAR 組成，用於治療兒童中樞神經系統(CNS)惡性腫瘤。透過合作，他們將利用西雅圖兒童治療工廠設施對新 CAR 進行早期臨床 GMP 研究。

2022年 3月，Twist Bioscience Corporation 和 Kriya Therapeutics, Inc. 簽署了一項抗體發現協議，在腫瘤治療應用中使用腺相關病毒(AAV)基因療法遞送抗體。合作後，兩家公司計劃將 Twist 的抗體庫與 Kriya 的專有載體工程平台結合，以發現針對特定目標的新型抗體，並透過 Kriya 的基因治療技術提供。

2022年 2月，Edigene Inc. 與波士頓兒童醫院(BCH)簽訂了一項全球許可協議，包括透過破壞關鍵基因來上調胎兒血紅蛋白的智慧財產權。胎兒血紅蛋白的上調是治療由異常血紅蛋白結構(血紅蛋白病)引起的許多遺傳性疾病的潛在治療方法，用胎兒版本的血紅蛋白分子替換有缺陷的血紅蛋白分子。

2022年 1月，FUJIFILM Corporation同意從 Atara Biotherapeutics, Inc. 收購一家細胞療法製造工廠。該工廠易於擴展，能夠靈活地生產臨床和商業細胞療法，包括同種異體 T 細胞和 CAR T 免疫療法。

2021年 1月，Thermo Fisher Scientific Inc收購了 Groupe Novasep SAS 旗下位於比利時的病毒載體製造業 Henogen SA。 Henogen 為生物技術公司和大型生物製藥客戶提供疫苗和治療藥物製造服務。透過此次收購，Thermo Fisher Scientific擴大了在細胞和基因疫苗及療法領域的能力。

因此，推出病毒載體、細胞治療製造培養基及同種異體T細胞等產品；開發針對各種健康問題的創新產品，以創造新的或改進的產品；透過合作和夥伴關係啟動新業務以保持市場競爭力，所有這些都有助於加速細胞和基因治療製造服務新平台的開發。因此，這些策略措施為細胞和基因治療製造服務市場創造了巨大的成長機會。

細胞和基因療法製造成本高昂

由於細胞和基因療法包括複雜的製造過程並使用生物成分，因此這些療法的價格過高。例如，Kymriah 的成本約為 475,000 美元，Yescarta 的成本約為 373,000 美元。根據臨床與經濟評論研究所(ICER)的分析，基因治療的平均成本為每劑100-200萬美元。細胞和基因療法的製造包括各種風險，例如黑盒子效應、放大失敗和靈活性降低。黑盒效應是指在自動化系統中執行的任務和流程；進程不可見，且進度狀態被隱藏。因此，缺乏對製造過程的可見性會增加故障並降低適應製造過程的靈活性。此外，製造商面臨的最嚴峻的挑戰是獲得 FDA 和 EMA 等監管機構的產品批准，並確保患者的安全免受治療副作用的影響。

此外，耗材和設備的成本要高得多，這導致細胞療法的成本高。例如，Miltenyi Biotec 提供的試劑盒價格從 500 美元到 5,000 美元不等。同樣，安裝設備的資本成本也接近200萬美元。因此，與治療價格有關的挑戰限制了細胞和基因治療製造服務市場的成長。

細胞和基因治療製造服務市場，依類型分析

根據類型，細胞和基因治療製造服務市場分為細胞治療和基因治療。細胞療法分為自體細胞療法和同種異體細胞療法。此外，基因治療分為病毒載體和非病毒載體。細胞治療領域在2022年佔據更大的市場佔有率。然而，基因治療領域預計在預測期內(2022-2030年)年複合成長率最高，達到 16.6%。基因療法是一種利用基因來預防、治療或治癒醫學病症或疾病的技術。基因療法通常透過用健康版本的基因替換患者細胞中的缺陷基因或添加損壞或缺失基因的新副本來發揮作用。基因療法可用於修改體內和體外的細胞。當使用基因療法修改體內細胞時，將攜帶基因的載體直接注射到患者體內。而當基因療法用於修改體外細胞並在實驗室中分離特定細胞類型時，會取出血液、骨髓或其他組織。

細胞和基因治療製造服務市場，透過基於適應症的洞察

根據適應症，細胞和基因治療製造服務市場分為癌症、骨科等。到2022年，癌症細分市場佔據最大市場佔有率，預計該細分市場在預測期內將以最高年複合成長率成長。細胞和基因治療的廣泛領域有望帶來許多有潛力預防癌症死亡的創新療法。根據癌症基因治療聯盟2022年 4月通訊報道，美國食品藥物管理局(FDA)已批准 6 種 CAR T 細胞療法用於治療骨髓瘤、白血病和淋巴瘤。2022年12月，FDA批准Adstiladrin，一種基於非複製腺病毒載體的基因療法，用於治療患有高危險卡介苗(BCG)無反應的非肌層浸潤​​性膀胱癌(NMIBC)的成人患者伴或不伴隨乳頭狀腫瘤的原位癌(CIS)。2022年，FDA 批准了 Kimmtrak，這是一種 T 細胞受體療法，用於治療眼葡萄膜黑色素瘤中一種罕見的黑色素瘤。隨著 FDA 批准用於治療癌症的細胞和基因療法數量的增加，這些療法的產量在過去幾年中也有所增加。因此，大量CDMO致力於為癌細胞和基因療法提供製造服務。

根據應用，細胞和基因治療製造服務市場分為臨床製造和商業製造。商業製造領域在2022年佔據最大市場佔有率，預計在預測期內(2020-2030年)年複合成長率最高，達到 17.1%。在臨床效益、耐用性和整體緩解率的共同推動下，CGT 在多個治療領域提供了巨大的價值。然而，這些療法尚未獲得顯著的市場影響力。由於向正確的患者提供正確的治療存在困難，CGT 的治療效果被低估，因此，在過去十年中，只有少數基於 CGT 的商業產品進入市場。然而，基於 CGT 的產品處於 3 期臨床試驗的臨床管道表明，在不久的將來批准數量可能會大幅增加。WuXi Advanced Therapies Inc.是一家著名的 CDMO，也是WuXi AppTec的全資子公司，宣佈於2021年 10月在上海開設新的製程開發和商業製造工廠。該新製造工廠將協助其透過 GMP 商業製造和整合測試服務將在未來幾年內支援CGT 產品的商業化。

依最終用戶分類，細胞和基因治療製造服務市場分為製藥和生物技術公司以及合約研究組織(CRO)。製藥和生物技術領域在2022年佔據最大市場佔有率，預計在預測期內(2020-2030年)年複合成長率最高，達到 17.1%。美國主要製藥和生物技術公司致力於提供用於治療急性和罕見疾病的 CGT，這些疾病對傳統方法沒有反應，其中包括 ElevateBio 和 Discovery Labs。這些公司致力於創建藥品合約開發和製造組織(CDMO)的全新分支。他們將透過投資資本利得稅相互競爭，並與少數大型服務公司競爭。

目錄

第1章 簡介

  • Insight Partners 研究報告指南
  • 市場區隔

第2章 執行摘要

  • 重要見解

第3章 研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第4章 細胞與基因療法市場格局

  • 概述
  • PEST分析

第5章 細胞和基因治療市場 - 主要產業動態

  • 主要市場促進因素：
    • 細胞和基因療法批准數量的增加
    • 外包細胞和基因治療製造越來越受歡迎
  • 市場限制
    • 細胞和基因療法製造成本高昂
  • 市場機會
    • 公司的策略舉措
  • 未來的趨勢
    • 細胞和基因治療製造服務的自動化
  • 影響分析：

第6章 細胞與基因治療市場 - 全球市場分析

  • 細胞和基因治療市場收入，2022 -2030

第7章 細胞和基因治療製造服務市場 - 收入和2030年預測 - 依類型

  • 概述
  • 細胞和基因治療製造服務市場收入佔有率，依類型2022年和2030年(%)
  • 細胞療法
  • 基因治療

第8章 2030年細胞和基因治療製造服務市場分析和預測 - 按指標

  • 概述
  • 細胞和基因治療製造服務市場，按適應症分類2022年和2030年(%)
  • 癌症
  • 骨科
  • 其他

第9章 細胞和基因治療製造服務市場 - 收入和2030年預測 -依應用

  • 概述
  • 2022年和2030年細胞和基因治療製造服務市場收入佔有率，依應用分類(%)
  • 臨床製造
  • 商業製造

第10章 細胞和基因治療製造服務市場 - 收入和2030年預測 - 依最終用戶

  • 概述
  • 2022年和2030年細胞和基因治療製造服務市場收入佔有率(依最終用戶分類)(%)
  • 製藥和生物技術公司
  • 合約研究組織(CRO)

第11章 細胞和基因治療製造服務市場 - 收入和2030年預測 - 區域分析

  • 北美：細胞和基因治療製造服務市場
    • 概述
    • 北美：2020-2030年細胞和基因治療製造服務市場(依類型)
      • 北美：細胞和基因治療製造服務市場，按細胞療法分類，2020-2030年
      • 北美：細胞和基因治療製造服務市場，按基因療法分類，2020-2030年
    • 北美：2020-2030年細胞和基因治療製造服務市場(按適應症)
    • 北美：2020-2030年細胞和基因治療製造服務市場(依應用)
    • 北美：細胞和基因治療製造服務市場，依最終用戶分類，2020-2030年
    • 北美：2022年和2030年細胞和基因治療製造服務市場(依地區)(%)
  • 歐洲：細胞與基因治療製造服務市場
    • 概述
    • 歐洲：2020-2030年細胞和基因治療製造服務市場(依類型)
      • 歐洲：細胞和基因治療製造服務市場，按細胞療法分類，2020-2030年
      • 歐洲：細胞和基因治療製造服務市場，按基因療法分類，2020-2030年
    • 歐洲：2020-2030年細胞和基因治療製造服務市場(按適應症)
    • 歐洲：2020-2030年細胞和基因治療製造服務市場(依應用)
    • 歐洲：細胞和基因治療製造服務市場，依最終用戶分類，2020-2030年
    • 歐洲：細胞和基因治療製造服務市場，依地區分類，2022年和2030年(%)
  • 亞太地區：細胞與基因治療製造服務市場
    • 概述
    • 亞太地區：2020-2030年細胞和基因治療製造服務市場(依類型)
      • 亞太地區：細胞與基因治療製造服務市場，依細胞療法分類，2020-2030年
      • 亞太地區：細胞和基因治療製造服務市場，按基因療法分類，2020-2030年
    • 亞太地區：2020-2030年細胞和基因治療製造服務市場(按適應症)
    • 亞太地區：2020-2030年細胞和基因治療製造服務市場(依應用)
    • 亞太地區：細胞和基因治療製造服務市場，依最終用戶分類，2020-2030年
    • 亞太地區：2022年和2030年細胞和基因治療製造服務市場(依地區)(%)
  • 中東和非洲：細胞和基因治療製造服務市場
    • 概述
    • 中東和非洲：2020-2030年細胞和基因治療製造服務市場(依類型)
      • 中東和非洲：細胞和基因治療製造服務市場，按細胞療法分類，2020-2030年
      • 中東和非洲：細胞和基因治療製造服務市場，按基因療法分類，2020-2030年
    • 中東和非洲：2020-2030年細胞和基因治療製造服務市場(按適應症)
    • 中東和非洲：2020-2030年細胞和基因治療製造服務市場(依應用)
    • 中東和非洲：細胞和基因治療製造服務市場，依最終用戶分類，2020-2030年
    • 中東和非洲：2022年和2030年依地區分類的細胞和基因治療製造服務市場(%)
  • 南美洲和中美洲：細胞和基因治療製造服務市場
    • 概述
    • 南美洲和中美洲：2020-2030年細胞和基因治療製造服務市場(依類型)
      • 南美洲和中美洲：細胞和基因治療製造服務市場，按細胞療法分類，2020-2030年
      • 南美洲和中美洲：細胞和基因治療製造服務市場，按基因療法分類，2020-2030年
    • 南美洲和中美洲：細胞和基因治療製造服務市場，按適應症分類，2020-2030年
    • 南美洲和中美洲：細胞和基因治療製造服務市場，依應用分類，2020-2030年
    • 南美洲和中美洲：細胞和基因治療製造服務市場，依最終用戶分類，2020-2030年
    • 南美洲和中美洲：細胞和基因治療製造服務市場，依地區分類，2022年和2030年(%)

第12章 細胞與基因療法製造服務市場 - 產業格局

  • 概述
  • 細胞和基因治療製造服務市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第13章 公司簡介

  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd?
  • Catalent Inc
  • Takara Bio Inc
  • Nikon Corp
  • FUJIFILM Holdings Corp
  • National Resilience Inc
  • Oxford BioMedica Plc
Product Code: TIPRE00024304

The cell and gene therapy manufacturing services market size is expected to grow from US$ 7,581.97 million in 2022 to US$ 26,724.90 million by 2030; it is estimated to register a CAGR of 17.1% during 2022-2030.

The report highlights trends prevailing in the market and the factors driving and hindering the cell and gene therapy manufacturing services market growth. The growth of the market is attributed increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing. However, high cost of cell and gene therapy manufacturing hinders the market growth.

Strategic Initiatives by Companies

Companies operating in the cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs.

In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Upon collaboration, the companies had plans of combining Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology.

In February 2022, Edigene Inc. entered into a global license agreement with Boston Children's Hospital (BCH) for intellectual property rights covering the upregulation of foetal haemoglobin by disrupting a key gene. Upregulation of foetal haemoglobin is a potential treatment for many genetic diseases resulting from abnormal haemoglobin structures (hemoglobinopathies), replacing the defective haemoglobin molecule with its foetal version.

In January 2022, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies, including allogeneic T-cell and CAR T immunotherapies.

In January 2021, Thermo Fisher Scientific Inc acquired Henogen S.A., the Belgium-based viral vector manufacturing business of Groupe Novasep SAS. Henogen provides vaccine and therapeutics manufacturing services to biotechnology companies and large biopharmaceutical customers. With this acquisition, Thermo Fisher Scientific expanded its capabilities in the cell and gene vaccines and therapies category.

Therefore, introducing products such as viral vectors, media for cell therapy manufacturing, and allogeneic T-cells; the development of innovative products targeting various health issues to create new or improved products; and the initiation of new businesses to remain competitive in the market, all, through collaborations and partnerships can help speed up the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives create significant growth opportunities in the cell and gene therapy manufacturing services market.

High Cost of Cell and Gene Therapy Manufacturing

As cell and gene therapies involve a complex manufacturing process and use biological components, these therapies are priced exorbitantly. For instance, the cost of Kymriah is ~US$ 475,000, and Yescarta is ~US$ 373,000, respectively. According to the analysis by the Institute for Clinical and Economic Review (ICER), the average cost of a gene therapy ranges US$ 1-2 million per dose. The manufacturing of cell and gene therapies involves various risks, such as the black-box effect, amplified failure, and reduced flexibility. The black-box effect refers to the tasks and processes performed in an automated system; there is no visibility to the process, and the progress status is hidden. Thus, the lack of visibility to the manufacturing processes increases failure and reduces the flexibility to adapt to the manufacturing processes. In addition, the most critical challenge for the manufacturers is to gain product approval from the regulatory bodies-such as FDA and EMA-and ensure patient's safety from the side effects of the therapy.

Furthermore, the cost of consumables and equipment is much higher, which leads to the premium cost of cell therapies. For instance, the cost of the reagent kit offered by Miltenyi Biotec ranges from US$ 500 to US$ 5,000. Similarly, the capital cost of installing the equipment is nearly US$ 2 million. Thus, the challenges pertaining to therapy prices limit the cell and gene therapy manufacturing services market growth.

Cell and Gene Therapy Manufacturing Services Market, By Type Insights

Based on type, the cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. The cell therapy segment held a larger market share in 2022. However, gene therapy segment is anticipated to register the highest CAGR of 16.6% during the forecast period (2022-2030). Gene therapy is a technique that uses a gene(s) to prevent, treat or cure a medical disorder or disease. Gene therapies often works by replacing a defective, or by adding new copies of a gene that is broken or missing gene in a patient's cells with a healthy version of that gene. Gene therapy can be used to modify cells outside as well as inside the body. A vector is injected carrying the gene directly into the patient when a gene therapy is used to modify cells inside the body. Whereas blood, bone marrow, or another tissue are taken out when gene therapy is used to modify cells outside the body and separate the specific cell types in the lab.

Cell and Gene Therapy Manufacturing Services Market, By Indication-Based Insights

Based on indication, the cell and gene therapy manufacturing services market is divided into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022 and same segment is expected to grow at the highest CAGR during the forecast period. The broad field of cell and gene therapy promises many innovative treatments that have the potential to prevent deaths from cancer. According to the April 2022 newsletter by Alliance for Cancer Gene Therapy, Inc., 6 CAR T-cell therapies have been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, leukemia, and lymphoma. In December 2022, the FDA approved Adstiladrin, a non-replicating adenoviral vector-based gene therapy, for the treatment of adult patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. In 2022, FDA approved Kimmtrak, a T-cell receptor therapy for a rare type of melanoma in the eye-uveal melanoma. As there is an increase in the number of FDA approvals of cell and gene therapy for the treatment of cancer, the production of these therapies has increased in the last several years. Thus, a large number of CDMOs are focusing on providing manufacturing services for cancer cell and gene therapies.

Based on Application, the cell and gene therapy manufacturing services market is categorized into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR of 17.1% in the market during the forecast period (2020-2030). CGTs provide significant value across multiple therapeutic areas, driven by a combination of clinical benefit, durability, and overall response rate. However, these therapies are yet to gain a significant market reach. The therapeutic gain of CGTs is underestimated due to the difficulty associated with delivering the right therapy to the right patients, and thus, only a few commercial CGTs-based products have reached the market over the past decade. However, the clinical pipeline of CGT-based products in Phase 3 clinical trials indicates the possibility of a dramatic rise in the number of approvals in the near future. WuXi Advanced Therapies Inc., a prominent CDMO and a wholly subsidiary of WuXi AppTec, announced the opening of new process development and commercial manufacturing facility in Shanghai in October 2021. This new manufacturing facility would help it expand its global capacity through GMP commercial manufacturing and integrated testing services that would support the commercialization of CGT products in the coming years.

The cell and gene therapy manufacturing services market, by end user, is categorized into pharmaceutical & biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR of 17.1% in the market during the forecast period (2020-2030). Major US-based pharmaceutical and biotechnology companies committed to offering CGTs intended to treat acute and rare conditions, which are unresponsive to traditional approaches, include ElevateBio and Discovery Labs. These companies are focused on creating a completely new branch of pharmaceutical contract development and manufacturing organizations (CDMOs). They would compete with one another and with a handful of giant services firms by investing in CGTs.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the cell and gene therapy manufacturing services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the cell and gene therapy manufacturing services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Cell and Gene Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Cell and Gene Therapy Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.3 Market Opportunities
    • 5.3.1 Strategic Initiatives by Companies
  • 5.4 Future Trends
    • 5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.5 Impact Analysis:

6. Cell and Gene Therapy Market - Global Market Analysis

  • 6.1 Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • 7.3 Cell Therapy
    • 7.3.1 Overview
    • 7.3.2 Cell Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.1 Autologous
        • 7.3.2.1.1 Overview
        • 7.3.2.1.2 Autologous: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.2 Allogenic
        • 7.3.2.2.1 Overview
        • 7.3.2.2.2 Allogenic: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Gene Therapy
    • 7.4.1 Overview
    • 7.4.2 Gene Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Viral Vector
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.2 Non-Viral Vector
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Non-Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

  • 8.1 Overview
  • 8.2 Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • 8.3 Cancer
    • 8.3.1 Overview
    • 8.3.2 Cancer: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Orthopedics
    • 8.4.1 Overview
    • 8.4.2 Orthopedics: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

  • 9.1 Overview
  • 9.2 Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • 9.4 Clinical Manufacturing
    • 9.4.1 Overview
    • 9.4.2 Clinical Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Commercial Manufacturing
    • 9.5.1 Overview
    • 9.5.2 Commercial Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

  • 10.1 Overview
  • 10.2 Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • 10.4 Pharmaceutical and Biotechnology Companies
    • 10.4.1 Overview
    • 10.4.2 Pharmaceutical & Biotechnology Companies: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5 Contract Research Organizations (CROs)
    • 10.5.1 Overview
    • 10.5.2 Contract Research Organizations (CROs): Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

11. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Regional Analysis

  • 11.1 North America: Cell and Gene Therapy Manufacturing Services Market
    • 11.1.1 Overview
    • 11.1.2 North America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.1.3 North America: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.1.3.1 North America: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.1.3.2 North America: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.1.4 North America: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.1.5 North America: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.1.6 North America: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.1.7 North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.1.7.1 US: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.7.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.7.1.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.1.7.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.1.7.1.3 US: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.1.7.1.4 US: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.1.7.2 Canada: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.7.2.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.2.1.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.7.2.1.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.1.7.2.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.1.7.2.3 Canada: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.1.7.2.4 Canada: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.1.7.3 Mexico: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.7.3.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.3.1.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.7.3.1.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.1.7.3.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.1.7.3.3 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.1.7.3.4 Mexico: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.2 Europe: Cell and Gene Therapy Manufacturing Services Market
    • 11.2.1 Overview
    • 11.2.2 Europe: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.2.3 Europe: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.2.3.1 Europe: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.2.3.2 Europe: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.2.4 Europe: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.2.5 Europe: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.2.6 Europe: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.2.7 Europe: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.2.7.1 Germany: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.1.1 Germany: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.1.1.1 Germany: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.1.2 Germany: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.2 Germany: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.1.3 Germany: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.1.4 Germany: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.2 UK: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.2.1 UK: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.2.1.1 UK: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.1.2 UK: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.2 UK: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.2.3 UK: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.2.4 UK: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.3 France: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.3.1 France: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.3.1.1 France: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.1.2 France: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.2 France: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.3.3 France: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.3.4 France: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.4 Italy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.4.1 Italy: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.4.1.1 Italy: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.1.2 Italy: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.2 Italy: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.4.3 Italy: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.4.4 Italy: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.5 Spain: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.5.1 Spain: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.5.1.1 Spain: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.1.2 Spain: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.2 Spain: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.5.3 Spain: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.5.4 Spain: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.6 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.6.1 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.6.1.1 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.1.2 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.2 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.6.3 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.6.4 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.3 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market
    • 11.3.1 Overview

.

    • 11.3.2 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.3.3 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.3.3.1 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.3.3.2 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.3.4 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.3.5 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.3.6 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.3.7 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.3.7.1 China: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.1.1 China: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.1.1.1 China: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.1.1.2 China: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.1.2 China: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.1.3 China: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.1.4 China: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.2 Japan: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.2.1 Japan: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.2.1.1 Japan: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.2.1.2 Japan: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.2.2 Japan: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.2.3 Japan: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.2.4 Japan: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.3 India: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.3.1 India: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.3.1.1 India: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.3.1.2 India: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.3.2 India: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.3.3 India: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.3.4 India: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.4 Australia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.4.1 Australia: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.4.1.1 Australia: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.4.1.2 Australia: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.4.2 Australia: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.4.3 Australia: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.4.4 Australia: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.5 South Korea: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.5.1 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.5.1.1 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.5.1.2 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.5.2 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.5.3 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.5.4 South Korea: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.6 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.6.1 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.6.1.1 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.6.1.2 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.6.2 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.6.3 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.6.4 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.4 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market
    • 11.4.1 Overview
    • 11.4.2 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.4.3 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.4.3.1 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.4.3.2 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.4.4 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.4.5 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.4.6 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.4.7 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.4.7.1 South Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.1.1 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.1.1.1 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.1.1.2 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.1.2 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.1.3 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.1.4 South Africa: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.4.7.2 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.2.1 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.2.1.1 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.2.1.2 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.2.2 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.2.3 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.2.4 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.4.7.3 UAE: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.3.1 UAE: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.3.1.1 UAE: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.3.1.2 UAE: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.3.2 UAE: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.3.3 UAE: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.3.4 UAE: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.4.7.4 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.4.1 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.4.1.1 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.4.1.2 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.4.2 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.4.3 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.4.4 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.5 South & Central America: Cell and Gene Therapy Manufacturing Services Market
    • 11.5.1 Overview
    • 11.5.2 South & Central America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.5.3 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.5.3.1 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.5.3.2 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.5.4 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.5.5 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.5.6 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.5.7 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.5.7.1 Brazil: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.5.7.1.1 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.5.7.1.1.1 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.5.7.1.1.2 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.5.7.1.2 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.5.7.1.3 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.5.7.1.4 Brazil: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.5.7.2 Argentina: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.5.7.2.1 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.5.7.2.1.1 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.5.7.2.1.2 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.5.7.2.2 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.5.7.2.3 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.5.7.2.4 Argentina: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.5.7.3 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.5.7.3.1 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.5.7.3.1.1 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.5.7.3.1.2 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.5.7.3.2 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.5.7.3.3 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.5.7.3.4 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

12. Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Thermo Fisher Scientific Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Merck KGaA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Charles River Laboratories International Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Lonza Group AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 WuXi AppTec Co Ltd?
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Catalent Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Takara Bio Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Nikon Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 FUJIFILM Holdings Corp
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 National Resilience Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Oxford BioMedica Plc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

List Of Tables

  • Table 1. Cell and Gene Therapy Market Segmentation
  • Table 2. Recent Organic Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
  • Table 3. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Manufacturing Services Market

List Of Figures

  • Figure 1. Cell and Gene Therapy Market Segmentation, By Geography
  • Figure 2. PEST Analysis
  • Figure 3. Cell and Gene Therapy Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030
  • Figure 6. Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • Figure 7. Cell Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Autologous: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Allogenic: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Gene Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Non-Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • Figure 14. Cancer: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Orthopedics: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Others: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 18. Clinical Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Commercial Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 21. Pharmaceutical & Biotechnology Companies: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Contract Research Organizations (CROs): Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. North America: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 24. North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 26. US: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. Canada: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Mexico: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Europe: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 30. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Europe: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 32. Germany: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 33. UK: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 34. France: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 35. Italy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 36. Spain: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 37. Rest of Europe: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 38. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 39. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 41. China: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 42. Japan: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 43. India: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 44. Australia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 45. South Korea: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 46. Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 47. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 48. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 49. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 50. South Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 51. Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 52. UAE: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 53. Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 54. South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 55. South & Central America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 56. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 57. Brazil: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 58. Argentina: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 59. Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 60. Growth Strategies in Cell and Gene Therapy Manufacturing Services Market